Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations

Background OX40 has been widely studied as a target for immunotherapy with agonist antibodies taken forward into clinical trials for cancer where they are yet to show substantial efficacy. Here, we investigated potential mechanisms of action of anti-mouse (m) OX40 and anti-human (h) OX40 antibodies,...

Full description

Saved in:
Bibliographic Details
Main Authors: Junping Jing, Laura Bover, C Ian Mockridge, Kerry L Cox, Mark S Cragg, Tatyana Inzhelevskaya, Chris A Penfold, Vikki English, Jane E Willoughby, Hong Shi, Peter J Morley, Heather Jackson, Roopa Srinivasan, Tom Murray, Axel Hoos, Paul Bojczuk, James Smothers, Niranjan Yanamandra, Lang Dou, Sabyasachi Bhattacharya, Laura Seestaller-Wehr, David Kilian, Kui S Voo, Mel John, Heather Niederer, Andrew J Shepherd, Laura Hook, Stephanie Hopley, Sara J Brett, Christopher Hopson, Elaine Paul, Stephen L Martin
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e008677.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items